Jeroen van Dorp

<i>Escherichia coli</i> –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Anne‐Gaëlle Goubet, Leonardo Lordello, Carolina Alves Costa Silva et al. · Cancer Discovery · 2022 · 70 citations · Full text

High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Jeroen van Dorp, Christodoulos Pipinikas, Britt B.M. Suelmann et al. · Nature Medicine · 2023 · 70 citations · Full text

Phase 1B, Urology, Genitourinary Cancer +8

Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer

Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras‐Sanz et al. · European Urology · 2022 · 45 citations · Full text

Prognostic Biomarkers, Urology, Genitourinary Cancer +8

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer

Sander Palit, Jeroen van Dorp, Daniël J. Vis et al. · Scientific Reports · 2021 · 15 citations · Full text

LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types

Leonie Voorwerk, Hannah Garner, Olga Blomberg et al. · Annals of Oncology · 2020 · 12 citations

Cancer Immunosurveillance, Immunology, Immune Checkpoint Inhibitor +7